In the spotlight: Prof. Twan Lammers, Aachen | New Scientific Webinars and Publications
November 10, 2020
Interview with a pioneering mind in nanomedicine and theranostics
Prof. Dr. Dr. Twan Lammers is Head of the Department Nanomedicine and Theranostics at the Institute for Experimental Molecular Imaging (ExMI) at the University Hospital Aachen and the Helmholtz Institute for Biomedical Engineering at RWTH Aachen University, Germany.
Ranked as one of the most highly cited researchers in Nanomedicine and Drug Delivery Systems, Prof. Lammers gives his perspective on the challenges involved with translating preclinical cancer nanomedicines into successful clinical therapies and on the disbalance between the many thousands of preclinical research papers published on cancer nanomedicines and the few successful cancer nanomedicine products that have reached the clinic. For the full interview, please click here.
Published research with MILabs equipment is booming
With many hundreds of peer-reviewed publications referencing MILabs molecular imaging equipment listed on our website, we aspire to share our customers’ knowledge to help propel the use of in-vivo imaging for preclinical research. Especially encouraging is a clear momentum for exploiting synergies offered by combining PET, SPECT, Optical, and CT on a single platform. Omni-tomography combinations, including Concurrent PET/SPECT, Simultaneous PET/PET, Theranostic Nuclear Imaging, and CT-guided Optical Tomography, push molecular imaging beyond today’s state-of-the-art technology. This enables never-before-possible preclinical research, as illustrated in examples below.
Recent research illustrating the power of multimodal synergistic imaging
1. Imaging and Therapy Against Hypoxic Tumors with 64Cu- ATSM using Concurrent PET-SPECT/CT acquisitions. Y. Fujibayashi, Y. Yoshii, T. Furukawa, M. Yoshimoto, H., T. Saga (2020). In: Y. Toyama, A. Miyawaki, M. Nakamura, M. Jinzaki (eds) Make Life Visible. Springer, Singapore. https://doi.org/10.1007/978-981-13-7908-6_29
Concurrent PET/SPECT of co-injected 99mTc-HSA and 64Cu-ATSM
2. Optical imaging of the whole-body to cellular biodistribution of clinical-stage PEG-b-pHPMA-based core-crosslinked polymeric micelles. I.Biancacci, Q. Sun, D. Möckel, et al., J of Cont Release (2020)
In this paper, it is shown that 3D OI/CT illustrates that core-crosslinked polymeric micelles (CCPM) efficiently target tumors in vivo. https://doi.org/10.1016/j.jconrel.2020.09.046
CT-guided Fluorescence Tomography of Cy7-labeled polymeric micelles
3. Multimodality Molecular Imaging of the Lung Disease using PET, CT, and Optical Imaging. A. Molotkov at al. WMIC Virtual 2020, ePoster.
CT-guided Fluorescence Tomography is used for quantifying the uptake of Cy7-albumin into abnormal epithelial permeability that is seen in various lung pathologies, including COVID-19, and acute respiratory distress (ARDS) after Intranasal delivery of lipopolysaccharides (LPS). Excellent correlation with 68Ga-albumin PET uptake.
Optical Tomography used to image ARDS such as caused by COVID-19
4. Polymeric Nanoparticles with Neglectable Protein Corona. I. Alberg et al., Small, May 2020.
In this paper MIlabs’ CT-guided Fluorescence Tomography was used to quantify circulation kinetics and biodistribution of the Cy7-labeled pHPMA nanoparticles in mice. Results showed excellent correlation with ex-vivo acquired images. https://doi.org/10.1002/smll.201907574
CT-guided Fluorescence Tomography to image biodistribution of nanoparticles in mice
5. Early Detection in a Mouse Model of Pancreatic Cancer by Imaging DNA Damage Response Signaling J. C. Knight et al., JNM, Dec. 2019
In this paper, it is shown that DNA damage imaging using γH2AX-TAT detects pancreatic cancer, whereas FDG fails https://pubmed.ncbi.nlm.nih.gov/31862800/
Concurrent PET/SPECT provides spatial and temporal co-registration
Free scientific pre-recorded webinars
MILabs’ high-res multimodal and integrated molecular imaging solutions are increasingly being deployed in many application fields, such as cancer research, drug development, immunology, cardiology, neurology, theranostics, and more, by pharmaceutical companies and universities, and research centers. MILabs has invited a number of experts whose research is facilitated by MILabs systems to conduct a series of on-demand webinars. You can find the webinars by clicking on the pictures or links below.
Dr. Kelly Ceyzériat, Hôpitaux Universitaires de Genève – Belle-Idée, Switzerland ‣ Simultaneous SPECT imaging of neurotransmitter systems in the brain: Using dual injections of radiotracers, U-SPECT imaging allows us to study two neurotransmitter systems in a single acquisition and consequently evaluate the interaction between them. Click here.
Dr. Stéphanie Durand-Panteix, University of Limoges, France
‣ MILabs U-SPECT/CT: applications of 212Pb therapy in multiple myeloma: The results of this study showed the efficacy of 212Pb-daratumumab in xenografted mice with significant tumor regression and increased survival. To conduct this preclinical study, in vivo biodistribution studies using U-SPECT/CT were performed. Click here
Prof. Ekaterina Dadachova, University of Saskatchewan, Canada
‣ Radioimmuno imaging & applications as supported by the MILabs VECTorCT platform at the University of Saskatchewan, including:
– Daratumumab-225Ac conjugate to enhance antitumor activity against experimental multiple myeloma tumors.
– Comparative radioimmunotherapy of experimental melanoma with novel humanized antibody to melanin labeled with 213Bi and 177Lu. Click here.
Prof. Dr. Freek Beekman, TU Delft, Founder and CEO MILabs
‣ Positron Range-Free and Multi-Isotope Tomography of Positron Emitters: Presentation from the IEEE NSS MIC virtual meeting 2020 in Boston to demonstrate that MIlabs’ magnified UHD-PET imaging achieves sub-mm resolution for isotopes with several mm positron range and enables dual-isotope TET imaging. Click here.